Astrazeneca Share Discussion Threads

[bluemango] 03/8/2021 22:54

Oversold.

14-day RSI is in low 20s (see charts in header)

[ariane] 03/8/2021 19:19

Upcoming events on ASTRAZENECA PLC

August/04/2021 Roadshow - Exane

August/04/2021 Roadshow - Goldman Sachs

August/04/2021 Roadshow - Citi

August/12/2021 Ex-dividend day for interim dividend

[dudishes] 01/8/2021 09:22

W, seems clear, nowt wrong with truth!

[waldron] 01/8/2021 09:09

CAMBRIDGE, Britain (AP) _ Astrazeneca PLC (AZN) on Thursday reported second-quarter profit of $550 million.

The Cambridge, Britain-based company said it had profit of 21 cents per share. Earnings, adjusted for non-recurring costs, came to 45 cents per share.

The pharmaceutical posted revenue of $8.22 billion in the period.

Astrazeneca shares have increased 14% since the beginning of the year. The stock has climbed almost 1% in the last 12 months.

This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on AZN at

[waldron] 01/8/2021 08:33

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

According to Refinitiv, the company's ESG score for its industry is good.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 71% by 2023.

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.

The group's high margin levels account for strong profits.

Over the past year, analysts have regularly revised upwards their sales forecast for the company.

Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.

For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.

Analysts covering this company mostly recommend stock overweighting or purchase.

Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company benefits from high valuations in earnings multiples.

The company's enterprise value to sales, at 4.46 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.

The company is highly valued given the cash flows generated by its activity.

The overall consensus opinion of analysts has deteriorated sharply over the past four months.

[waldron] 31/7/2021 17:05

WISHFUL THINKING PERHAPS FOR THE LONG LONG TERM TARGET


Should be fun to chalk it up BOX BY BOX

THE AZN WISH LIST BOXES togetherwith Broker targets thrown in for good measure to make you laugh,chuckle,smile and or smirk


6975 to 7475p
7475 to 7975p
7975 to 8475p$$$$$$$$$$ WE ARE HERE TODAY $$$$$$$$$$$$$$$$$$$
8475 to 8975p
8975 to 9475p $$$$$$$$$$$Credit Suisse targets 9000p
9475 to 9975p
9975 to 10475p $$$$$$$$$$ Barclays goes for a 10000p target

December 2019 ended at 7654p

December 2020 ended at 7324p

July 2021 ends at 8268p

Mean consensus OUTPERFORM

Number of Analysts 29

Average target set at 9616p $$$$$$$$ Near EV of 9475p $$$$$$$$$$

Highest target 11748p

Lowest target 6894p

Current supports 8253p and then 7632p

Current resistences 8480p and then 8779p



Credit Suisse is positive on the stock with a Buy rating. The target price is unchanged and still at GBX 9000.

[waldron] 31/7/2021 13:47

The average target seems to be approx 9616 which might be achieved as the earnings release is approaced on 12th November if resistences of 8490p and 8779p are breached

Current strong supports seem to be 8253p and then 7632p

[waldron] 31/7/2021 12:04

Ex-div date 12 Aug 2021 (Thu)

Pay date 13 Sep 2021 (Mon)

64.8p per share

[grupo guitarlumber] 30/7/2021 22:01

07/30/2021 | 11:47am BST


Credit Suisse is positive on the stock with a Buy rating. The target price is unchanged and still at GBX 9000.

Looks like rhey are pencilling in the EV

[grupo guitarlumber] 30/7/2021 21:40

The record date for the first interim dividend for 2021, payable on 13 September 2021, will be 13 August 2021. The ex-dividend date will be 12 August 2021.

[jimarilo] 30/7/2021 17:19

Doctors for Covid Ethics Symposium Day two.......live now !!



Reiner Fuellmich over 500,000 deaths from the vax in the USA

[brummy_git] 30/7/2021 15:17

AstraZeneca was discussed briefly here on today's Vox 'Stock Picking' videocast (starts 40:10).

www.linkedin.com/posts/paul-hill-a5994116_stocks-to-follow-with-justin-waite-and-paul-activity-6826865195483242496-ww3t

[beckers2008] 30/7/2021 12:45

ASTRAZENECA : Receives a Buy rating from Credit Suisse
07/30/2021 | 11:47am BST

Credit Suisse is positive on the stock with a Buy rating. The target price is unchanged and still at GBX 9000.

[montyhedge] 30/7/2021 08:09

Good idea, if no profit on covid vaccines.

[smcni1968] 29/7/2021 14:55

Looking to sell the COVID vaccine business

[montyhedge] 29/7/2021 08:04

No dividend increase once again.

[alphorn] 29/7/2021 07:35

......also benefitting from sales of the pandemic COVID-19 vaccine of $572m.

Quite a big number; particulary as it remains unapproved in some big markets.

[steeplejack] 29/7/2021 07:18

Interims.A very solid set of figures.- Reported EPS of $1.61 in the half represented an increase of 37% (45% at CER). Core EPS grew by 26% (27% at CER) to $2.53. Reported and Core EPS were adversely impacted by $0.04 due to the pandemic COVID-19 vaccine - An unchanged first interim dividend of $0.90 (64.8 pence, 7.77 SEK) per ordinary share

[bluemango] 23/7/2021 12:34

Relevant to the above, is the data on UK vaccination progress. Easier to justify charging a realistic rate to ROW when most in this country have now had the jab.

"So far, more than 46 million people have had a first vaccine dose - nearly 90% of the adult population - and more than 36 million - about 70% of adults - have had both doses"

[bluemango] 23/7/2021 12:31

The tricky thing for Astra now, balancing their public image against shareholders' interests, is the timing of declaring when it is no longer a pandemic and therefore they can start adding a profit margin on the vaccine.

There were reports a while ago that July might be the time for that, though maybe that's looking a bit early. Interims in 6 days' time might shed some light on the company's current thinking.

[smcni1968] 23/7/2021 11:44

Probably to do with closing the Alexion acquisition

[philanderer] 23/7/2021 11:00

Fri, 23rd Jul 2021 10:30


(Alliance News) - AstraZeneca PLC on Friday said results from a recent study show its Covid-19 vaccine is "highly effective" after one dose against severe disease or hospitalisation caused by all major variants of the coronavirus.

The vaccine was 82% effective against hospitalisation and death caused by the Beta and Gamma variants, real-world data from Canada showed. Effectiveness rises to 87% against the Delta variant and 90% against the Alpha variant.

[bluemango] 22/7/2021 18:02

Curious.

A similar thing happened with TCAP a few days ago. Out of nowhere, a 12% short by Phase 2 suddenly appeared on shorttracker and a couple of other websites. Then within just a day or so, it had vanished. No-one seems to know if was just a glitch or whatever but it's not open now. Someone said they were reporting this with the FCA; don't know if they had any response.